Dogwood Therapeutics, Inc. DWTX
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- -70.67%
- 1 year
- -80.35%
- Open
- 1.29
- Prev close
- 1.28
- Mkt cap
- 46.64M
- Vol
- 38.85K
- Avg vol
- 69.91K
- EPS
- 2.17
- P/E
- 0.56
- Div yield
- 0.00%
More statistics
- Low
- 1.20
- High
- 1.29
- Forward P/E
- -0.43
- Beta
- 0.00
- Short ratio
- 0.42
- Inst. own
- 3.24%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 3.32
- 200-d avg
- 6.07
- 1y target
- 13.83
News
-
2 weeks ago benzinga.com
Dogwood Therapeutics Enters Into Securities Subscription Agreement For $5 Investment From CK Life Sciences’ Subsidiary
- Largest Shareholder Increases Position as Dogwood Advances Halneuron® Toward Topline Phase 2b Data Readout in November 2026 -- Expected Proceeds from the Investment Enable Acceleration of Phase 3…
3 weeks ago globenewswire.com
Dogwood to Participate in the 2026 Maxim Growth Summit
ATLANTA, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and…
1 month ago globenewswire.com
Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
- Enrollment of 239 Patients Meets Upper End of Planned Enrollment Target Range - - Topline Data Expected in November 2026 - ATLANTA, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc.…
1 month ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million. Corbus Pharmaceuticals
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Immuron (NASDAQ:IMRN) stock increased by 64.9% to $1.83 during Friday's pre-market session. The company's market cap stands at $8.9 million. Akanda (NASDAQ:AKAN) shares increased by 27.52% to…
2 months ago seekingalpha.com
Dogwood Therapeutics, Inc. (DWTX) Discusses Halneuron and Pipeline Advances for Chemotherapy-Induced Neuropathic Pain Transcript
Dogwood Therapeutics, Inc. (DWTX) Discusses Halneuron and Pipeline Advances for Chemotherapy-Induced Neuropathic Pain Transcript
2 months ago marketbeat.com
Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment
Dogwood Therapeutics NASDAQ: DWTX said its Phase 2b study of Halneuron, an investigational treatment for chemotherapy-induced neuropathic pain, has enrolled more than 230 patients and is expected to…
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers bioAffinity Technologies (NASDAQ:BIAF) shares increased by 68.4% to $7.68 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.7 million. Lakewood-Amedex…
2 months ago globenewswire.com
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid…
-
2 months ago benzinga.com
Dogwood Therapeutics Q2 EPS $(0.34) Misses $(0.14) Estimate
Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.14) by 142.86 percent. This is a 82.91 percent increase over…
2 months ago globenewswire.com
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results
- Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026, 217 patients enrolled –
3 months ago defenseworld.net
Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 4.3% – What’s Next?
Dogwood Therapeutics, Inc (NASDAQ: DWTX - Get Free Report) shares traded up 4.3% during trading on Monday. The stock traded as high as $1.74 and last traded at $1.71. Approximately 83,119 shares were…
-
3 months ago benzinga.com
Dogwood Therapeutics Admits First 200 Participants In Its Current HAL-CINP Phase 2b Study To Evaluate Efficacy, Safety Of Halneuron
Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has successfully…
3 months ago globenewswire.com
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy,…
4 months ago globenewswire.com
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
Veteran Biopharma Executive and Venture Investor to Lead Newly Formed Dogwood Advisory Board in advance of Halneuron® Phase 2b Data Which is Projected for Fall of 2026 Veteran Biopharma Executive and…
4 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
4 months ago seekingalpha.com
Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript
Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript
-
5 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Dogwood Therapeutics, Maintains $12 Price Target
HC Wainwright & Co. analyst Sean Lee reiterates Dogwood Therapeutics (NASDAQ:DWTX) with a Buy and maintains $12 price target.
-
5 months ago benzinga.com
Dogwood Therapeutics Starts New Halneuron Hemotherapy Induced Neuropathic Pain Phase 2b Extension Trial
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a biopharmaceutical company developing first-in-class, non-opioid medicines to treat pain and neuropathy, today announced…
5 months ago globenewswire.com
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
New study to assess Halneuron ® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package
-
5 months ago benzinga.com
Dogwood Therapeutics Q1 EPS $(0.15), Inline
Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 98.22 percent increase over losses of $(8.45) per share from the…
5 months ago globenewswire.com
Dogwood Therapeutics Announces First Quarter 2026 Financial Results
- Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 -
5 months ago globenewswire.com
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
ATLANTA, May 07, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing new medicines to treat pain and neuropathy,…
-
6 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Dogwood Therapeutics, Maintains $12 Price Target
HC Wainwright & Co. analyst Sean Lee reiterates Dogwood Therapeutics (NASDAQ:DWTX) with a Buy and maintains $12 price target.
-
6 months ago benzinga.com
Dogwood Therapeutics Partners With PRIDCor Therapeutics To Advance Its Anti-Viral Candidates IMC-1 And IMC-2
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a company that focuses on developing new medicines to treat pain and neuropathy, today announced a global development and…
6 months ago globenewswire.com
Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
- PRIDCor Therapeutics Granted Global Development and Commercialization License for IMC-1 and IMC-2 Assets for All Indications, including Fibromyalgia and Long-COVID - - Dogwood Granted a Tiered…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
6 months ago benzinga.com
Dogwood Therapeutics Announces FDA Acceptance Of IND Application For Development Candidate SP16, Administered IV, For Treatment Of Chemotherapy-Induced Pain And Peripheral Neuropathy
Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin PharmaThe SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected…
6 months ago globenewswire.com
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected…
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
7 months ago defenseworld.net
Analyzing REGENXBIO (NASDAQ:RGNX) and Dogwood Therapeutics (NASDAQ:DWTX)
REGENXBIO (NASDAQ: RGNX - Get Free Report) and Dogwood Therapeutics (NASDAQ: DWTX - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two…
7 months ago defenseworld.net
Dogwood Therapeutics (DWTX) to Release Quarterly Earnings on Monday
Dogwood Therapeutics (NASDAQ: DWTX - Get Free Report) is projected to issue its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of…
-
7 months ago benzinga.com
Dogwood Therapeutics Q4 EPS $(0.26) Beats $(1.17) Estimate
Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(1.17) by 77.83 percent. This is a 95.87 percent increase over losses…
7 months ago globenewswire.com
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy,…
7 months ago defenseworld.net
Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 1.7% – Time to Buy?
Shares of Dogwood Therapeutics, Inc (NASDAQ: DWTX - Get Free Report) were up 1.7% during mid-day trading on Friday. The company traded as high as $3.17 and last traded at $3.06. Approximately 49,806…
-
8 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Dogwood Therapeutics, Maintains $12 Price Target
HC Wainwright & Co. analyst Sean Lee reiterates Dogwood Therapeutics (NASDAQ:DWTX) with a Buy and maintains $12 price target.
9 months ago globenewswire.com
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron ® treatment to be well tolerated - ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood…
-
9 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Dogwood Therapeutics, Maintains $12 Price Target
HC Wainwright & Co. analyst Sean Lee reiterates Dogwood Therapeutics (NASDAQ:DWTX) with a Buy and maintains $12 price target.
-
9 months ago benzinga.com
Dogwood Therapeutics Highlights Pipeline Expansion And Clinical Progress Toward Non-Opioid Cancer Pain And Neuropathy Treatments; Key Halneuron And SP16 Milestones Targeted For 2026
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("DWTX" or "Company"), a company that focuses on developing new non-opioid medicines to treat pain and neuropathy, issues a corporate update in the following…
-
10 months ago benzinga.com
What's Driving the Market Sentiment Around Dogwood Therapeutics Inc?
What's Driving the Market Sentiment Around Dogwood Therapeutics Inc?
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
10 months ago benzinga.com
Dogwood Therapeutics Reports Interim Results For Halneuron In Chemotherapy-Induced Neuropathic Pain Study; Expects Top-Line Results Availability In Q3 2026
- Halneuron® treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 -- The overall study dropout rate of ~4.4% is far below…
-
11 months ago benzinga.com
Dogwood Therapeutics Files For New Intellectual Property Protection For Synthetic Halneuron
Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has filed for new…
-
11 months ago benzinga.com
Dogwood Therapeutics Launches $8.56M At-The-Market Stock Offering Under New Equity Distribution Agreement
On November 28, 2025, Dogwood Therapeutics, Inc., a Delaware corporation (the "Company"), entered into an Equity Distribution Agreement (the "Agreement") with Northland Securities, Inc. (trade
-
11 months ago benzinga.com
Dogwood Therapeutics Enrolls First 100 Patients In Ongoing HALT-CINP Phase 2b CINP Trial
- Continued low early termination rate among the first 80 study completers suggests Halneuron® and placebotreatmenthave been well toleratedATLANTA, GEORGIA / ACCESS Newswire / November 11, 2025 /…
-
12 months ago benzinga.com
Dogwood Therapeutics Q3 EPS $(8.20) Misses $(1.58) Estimate
Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(8.20) per share which missed the analyst consensus estimate of $(1.58) by 418 percent. This is a 300 percent decrease over losses of…
-
1 year ago benzinga.com
Dogwood Therapeutics Announces Its CMO Will Present An Overview Of The Halneuron Pain Management Research Program At 19th Annual Pain Therapeutics Summit On October 14, 2025
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain, today announced that its Chief Medical Officer will present…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
1 year ago benzinga.com
Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket
Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket